This page is research and education. It is not medical advice and it is not a place to buy Ozempic, Mounjaro, or any other brand drug. FLX Peptides is not a pharmacy. Prescription GLP-1 medicines come from a licensed clinician and a licensed pharmacy. Research-use listings are a different category. Do not mix those two up.
If you want help sorting the names, the class, and the sourcing noise, book a consult.
What "GLP-1" actually means
GLP-1 is a hormone your gut already makes. It is involved in insulin signaling, appetite, and how fast the stomach empties. A GLP-1 receptor agonist is a compound that binds that receptor and turns the pathway on.
That is the class. The brand names are products inside the class. People use the words as if they were the same thing. They are not.
When someone says "I'm on a GLP-1," they might mean:
- A prescription pen from a manufacturer, filled by a pharmacy.
- A compounded product from a compounding pharmacy, if one is even available and lawful for that molecule in their situation.
- A research-use vial sold under a chemical name.
- A social-media nickname with no paperwork behind it.
Those are not interchangeable. The receptor story can be similar. The supply chain, the legal status, and the quality system are not.
The names people actually type
Search is messy. This is the map, kept high-level and without invented numbers.
Semaglutide / Ozempic
Semaglutide is a GLP-1 receptor agonist. Ozempic is a well-known brand of semaglutide. People also know related brand names for other approved uses of the same molecule. Those are prescription products. FLX does not sell them and this page is not a coupon or a workaround.
If you are researching the chemical name, say semaglutide. If you are talking about a specific approved pen, say the brand your clinician prescribed. Mixing the two is how people end up comparing a pharmacy carton to a lyophilized vial from a website.
Tirzepatide / Mounjaro (and "Monjaro")
Tirzepatide is a dual agonist. It targets the GIP receptor and the GLP-1 receptor. Mounjaro is a well-known brand of tirzepatide. People misspell it Monjaro constantly — same drug name, same search intent.
Tirzepatide is not "a stronger Ozempic." It is a different molecule with a different receptor profile. Whether that matters for a given person is a clinical question, not a forum ranking.
Retatrutide / "reta"
Retatrutide is Eli Lilly's investigational triple agonist. It is designed to hit GLP-1, GIP, and glucagon receptors. It is not an approved brand drug sitting next to Ozempic and Mounjaro on a pharmacy shelf.
Reta is the shorthand you will see in forums, Discord servers, and research-vendor menus. Shorthand is not a specification. If a listing only says "reta" and cannot name the molecule, the lot, and a real COA, you do not know what you are looking at.
Investigational means the clinical program is still the source of truth — not TikTok, and not a research catalog.
A class comparison, not a sales sheet
Keep the comparison at the receptor level. That is the part that is actually educational.
| Name people use | Molecule | Receptor story (high level) | Status people confuse |
|---|---|---|---|
| Ozempic, "sema" | Semaglutide | GLP-1 receptor agonist | Approved brand drug vs. research-use listings of the chemical name |
| Mounjaro, "Monjaro," "tirz" | Tirzepatide | Dual GIP and GLP-1 agonist | Approved brand drug vs. research-use listings |
| Reta, retatrutide | Retatrutide | Investigational triple agonist (GLP-1, GIP, glucagon) | Not an approved retail brand; research talk and trial talk get flattened into one word |
What this table is not:
- A ranking of "best for weight loss."
- A reason to switch products.
- A claim that a research vial equals a manufacturer pen.
Weight change is the headline. The underlying biology is broader — appetite, gastric emptying, glucose handling, and, in the triple-agonist conversation, energy expenditure via the glucagon piece. Broader is not the same as "better for you." It means the class is not only a scale story. It also means side-effect conversations (nausea, fullness, constipation, muscle loss if protein and training are ignored) belong in the same breath as the headline.
Why this is not a pharmacy page
Ozempic and Mounjaro are prescription medicines. If that is the path someone is on, the next conversation is with their prescriber and their pharmacy — not with a research-use catalog.
FLX Peptides / Better You FLX does education, sourcing guidance, and 1-on-1 coaching. There is no live checkout here for those brand drugs. We will not write "buy Ozempic here" or "buy Mounjaro here." We will not treat a research listing as a substitute pen.
If you are trying to understand a research-use listing that uses these chemical names, that is a quality and labeling problem. It is not a back door into a brand product.
Why coaching matters
Most of the damage in this category is not from people reading a mechanism paragraph. It is from people skipping the unglamorous parts.
Nutrition. Appetite drops. Protein often drops with it. People lose weight and also lose the training they were trying to protect. A coach can talk through food, protein, and resistance work without pretending that is a prescription.
Titration conversations. Approved products have clinician-directed schedules. Research listings do not inherit those schedules. We will not publish a dose ladder that looks like a script. We will talk about why "start low, go slow" exists as a clinical idea, what to ask a prescriber, and why copying someone else's pen clicks is a bad plan.
Sourcing confusion. "Sema," "tirz," and "reta" get sold in the same aesthetic as a recovery peptide. The paperwork is not the same. A source check still applies: lot-matched COA, real lab, identity method, no recycled PDFs. If you want an item requested, use Sources.
Expectations. These compounds are not a personality transplant. They do not replace sleep, steps, or a clinician for diabetes or other diagnosed conditions.
Josh's coaching through Better You FLX is 1-on-1. Plain language. No gatekeeping. No hype ranking of brand names.
Research use, not medical advice
Nothing here is a diagnosis, a dose, or permission to use a research chemical in a person. Prescription GLP-1 medicines are between you and a licensed clinician. Research-use materials are Research Use Only. If you cannot tell which one you are looking at, stop and ask.
Questions also go through Contact. Phone: 315-359-1527.
Book a consult
If you want a direct conversation about GLP-1s, tirzepatide, retatrutide / reta, nutrition, or sourcing confusion — not a sales pitch for a brand pen — book a 1-on-1 consult with Better You FLX.
https://www.flxpeptides.com/consult